Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search
		×
			Vaccines site
			Vaccines site
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


Vaccine Recommendations and Guidelines of the ACIP


Section Navigation
			
			CDC Home








COVID-19 ACIP Vaccine RecommendationsAdvisory Committee on Immunization Practices (ACIP)						Print
																Related Pages
										Published in Morbidity and Mortality Weekly Report (*MMWR*)
The Advisory Committee on Immunization Practices (ACIP) provides advice and guidance to the Director of the CDC regarding use of vaccines and related agents for control of vaccine-preventable diseases in the civilian population of the United States. Recommendations made by the ACIP are reviewed by the CDC Director and, if adopted, are published as official CDC/HHS recommendations in the Morbidity and Mortality Weekly Report (MMWR).See **Clinical Considerations for Use of COVID-19 Vaccines**CURRENT COVID-19 Vaccine Recommendations
MMWR, October 20, 2023, Vol 72(42);1140–1146Use of Updated COVID-19 Vaccines 2023–2024 Formula for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2023
Print version [7 pages]
See also:
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Updated COVID-19 vaccine (2023-2024 Formulation) | CDC
EtR framework for Use of an Updated (Monovalent XBB Containing) COVID-19 Vaccine Under an Emergency Use Authorization | CDCARCHIVED COVID-19 **Immunization Publications**
For your convenience, these archived publications can be used for historical and research purposes.
*MMWR*, June 16, 2023, Vol 72(24);657–662Interim Recommendations for Use of Bivalent mRNA COVID-19 Vaccines for Persons Aged ≥6 Months — United States, April 2023
Print version [6 pages]
*MMWR*, November 11, 2022, Vol 71(45); 1436-1441Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines — United States, October 2022 | MMWR (cdc.gov)
Print version [6 pages]
See also:
ACIP Evidence to Recommendations (EtR) for Use of Bivalent COVID-19 Vaccine Booster Doses under an Emergency Use Authorization | CDC
ACIP Evidence to Recommendations (EtR) for Use of Novavax COVID-19 Vaccine Booster Dose for adults ages 18 years and older under an Emergency Use Authorization | CDC
*MMWR*, August 4, 2022, Vol 71(31); 988-992Interim Recommendation of the Advisory Committee on Immunization Practices for use of the Novavax COVID-19 vaccine in persons aged 18 years and older— United States, July 2022
Print version [5 pages]
See also:
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Novavax COVID-19 Vaccine (cdc.gov)
ACIP Evidence to Recommendations for Use of Novavax COVID-19 Vaccine, Adjuvanted in adults ages 18 years and older under an Emergency Use Authorization (cdc.gov)
The Novavax COVID-19 Vaccine’s Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events (cdc.gov)
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Moderna COVID-19 Vaccine for Children Aged 6–11 Years
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Moderna COVID-19 Vaccine for Persons Aged 12-17 Years
ACIP Evidence to Recommendations for Use of Moderna COVID-19 Vaccine in Children Ages 6 – 11 years and Adolescents Ages 12 – 17 years under an Emergency Use Authorization
*MMWR,* June 28, 2022, Vol 71(26);859–868Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months–5 Years — United States, June 2022
Print version [10 pages]
See also:
GRADE: Moderna COVID-19 Vaccine for Children Aged 6 Months–5 Years | CDC
GRADE: Pfizer-BioNTech COVID-19 Vaccine for Children Aged 6 Months–4 Years | CDC
ACIP Evidence to Recommendations for Use of Moderna COVID-19 Vaccine in Children Ages 6 Months – 5 Years and Pfizer-BioNTech COVID-19 Vaccine in Children Ages 6 Months – 4 Years under an Emergency Use Authorization | CDC
Moderna COVID-19 Vaccine’s  Reactions and Adverse Events | CDC
Pfizer-BioNTech COVID-19 Vaccine Reactions & Adverse Events | CDC
EtR Update for a Pfizer-BioNTech COVID-19 Booster in Children Ages 5-11 Years
EtR Framework for a 2nd COVID-19 Booster Dose in Adults Ages 50 Years and Older and Immunocompromised Individuals
*MMWR*, March 18, 2022, Vol 71(11);416–421Use of Moderna COVID-19 Vaccine in Persons Aged ≥18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19 Vaccines — United States, February 2022
Print version [6 pages]
See also:
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Moderna COVID-19 Vaccine | CDC
ACIP Evidence to Recommendations for Use of Moderna COVID-19 Vaccine | CDC
*MMWR*, January 21, 2022, Vol 71(3);90–95Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices – United States, December 2021
Print version [6 pages]
*MMWR*, November 5, 2021, Vol 70(45);1579–1583Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5–11 Years — United States, November 2021
Print version [5 pages]
*MMWR*, November 5, 2021, Vol 70(44);1545–1552Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines — United States, 2021
Print version [8 pages]
See also:
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Pfizer-BioNTech, Moderna, and Janssen COVID-19 booster doses
ACIP Evidence to Recommendations for Use of an Additional COVID-19 Vaccine Dose in Immunocompromised People
ACIP Evidence to Recommendations for Use of COVID-19 Vaccine Booster Doses
*MMWR*, September 24, 2021, Vol 70(38);1344–1348Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2021
Print version [5 pages]
See also:
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Pfizer-BioNTech COVID-19 Vaccine
ACIP Evidence to Recommendations for Use of Pfizer-BioNTech COVID-19 Vaccine
*MMWR*, August 13, 2021, Vol 70(32);1094-1099Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021
Print version [6 pages]
*MMWR*, July 9, 2021, Vol 70(27);977–982Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021
Print version [6 pages]
*MMWR*, May 14, 2021, Vol 70(20);749–752The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12–15 Years — United States, May 2021
Print version [4 pages]
See also:
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Pfizer-BioNTech COVID-19 Vaccine for Persons Aged 12-15 Years
ACIP Evidence to Recommendations for Use of Pfizer-BioNTech COVID-19 Vaccine under an Emergency Use Authorization
Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events: Pfizer-BioNTech COVID-19 Vaccine
*MMWR*, April 30, 2021, Vol 70(17);651-656Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021
Print version [6 pages]
See also:
Risk-Benefit Analysis
*MMWR*, March 2, 2021, Vol 70(9);329–332The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021
Print version [4 pages]
See also:
ACIP Evidence to Recommendations for Use of Janssen COVID-19 Vaccine under an Emergency Use Authorization
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Janssen COVID-19 Vaccine
Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events: Janssen COVID-19 Vaccine
*MMWR*, December 22, 2020, Vol 69(5152);1657-1660The Advisory Committee on Immunization Practices’ Updated Interim Recommendation for Allocation of COVID-19 Vaccine — United States, December 2020
Print version [5 pages]
See also:
Evidence Table for COVID-19 Vaccines Allocation in Phases 1b and 1c of the Vaccination Program*MMWR*, December 20, 2020, Vol 69(5152);1653-1656The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Moderna COVID-19 Vaccine — United States, December 2020
Print version [4 pages]
See also:
Evidence to Recommendations
GRADE Evidence Tables
Interim Clinical Considerations
Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events*MMWR*, December 13, 2020, Vol 69(50);1922-1924The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine — United States, December 2020
Print version [3 pages]
See also:
Evidence to Recommendations
GRADE Evidence Tables
Interim Clinical Considerations
Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events
Interim Considerations: Preparing for the Potential Management of Anaphylaxis at COVID-19 Vaccination Sites
*MMWR*, December 3, 2020, Vol 69(49);1857-1859The Advisory Committee on Immunization Practices’ Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine — United States, 2020
Print version [3 pages]
See also:
Evidence TableTop of Page
							
					
							Last Reviewed:  December 12, 2023						Source: 	National Center for Immunization and Respiratory Diseases
					Facebook
        Twitter
        LinkedIn
        Syndicate homeACIP Recs Home
Vaccine-Specific Recommendationsplus icon
Anthrax
Cholera
COVID-19
Dengue
DTaP/IPV/Hib/HepB
DTaP/Tdap/Td
Ebola
Hepatitis A
Hepatitis B
Hib
HPV
Influenza
Japanese Encephalitis
MMR
MMRV
Meningococcal
Pneumococcal
Polio
Rabies
Rotavirus
RSV
Smallpox
TBE
Typhoid
Varicella
Yellow Fever
Zoster (Shingles)
Recs Listed by Date
Comprehensive Recommendations and Guidelinesplus icon
General Best Practice Guidelinesplus icon
Introduction
History
Timing and Spacing of Immunobiologics
Contraindications and Precautions
Preventing and Managing Adverse Reactions
Vaccine Administration
Storage and Handling of Immunobiologics
Altered Immunocompetence
Special Situations
Vaccinations Records
Vaccination Programs
Vaccine Information Sources
Appendix 1: Glossary
Appendix 2: Membership
Archived ACIP Recs
Vaccine Recommendations for Emergency Situations To receive email updates about this page, enter your email address: Email Address			What's this?				Submit
 Vaccines & ImmunizationsVFC ResolutionsACIP Web SiteCDC's International Travelers Yellow BookClinical Travel Notices, Updates, and Vaccine Shortages


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue